A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Clinical trial NCT06570798 · RECRUITING

Trial details

NCT number: NCT06570798
Sponsor: Amgen
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Systemic Lupus Erythematosus Active Refractory Rheumatoid Arthritis

Start date: 2025-07-16
Primary completion: 2028-08-06
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.